Author

A. M. Hernandez

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Benefit of upfront combination lipid-lowering therapy in statin-naïve acute coronary syndrome patients with intermediate admission LDL-C and Lp(a)-driven predicted monotherapy failure

The proportion of LLT-naïve ACS patients eligible for upfront combination therapy due to Lp(a)-driven predicted monotherapy failure (Lp(a)-PMF) is identified, and the real-world benefit of this strategy in achieving the absolute therapeutic target (LDL-C <55 mg/dL) is evaluated.

F. B. Santiago, J. M. Andreu Cayuelas, A. M. Hernandez et al. · European Heart Journal · 0 citations

Open access Oct 2026

Association of apolipoprotein B and lipoprotein(a) with severe atherosclerotic cardiovascular disease in patients with acute coronary syndrome: the modifying effect of prior lipid-lowering therapy.

The interplay between apolipoprotein B (apoB) and Lipoprotein(a) [Lp(a)] in determining atherosclerotic cardiovascular disease (ASCVD) severity remains complex, particularly under the influence of lipid-lowering therapy (LLT). To evaluate the association of apoB and Lp(a) with severe ASCVD in patients hosp...

A. M. Hernandez, F. B. Santiago, J. M. Andreu Cayuelas et al. · European Heart Journal · 0 citations

Open access Oct 2026

Upfront combination lipid-lowering therapy in statin-naive acute coronary syndrome patients with high admission LDL-C: real-world support for the 2025 ESC dyslipidaemias guidelines

The findings strongly support the 2025 ESC/EAS Guidelines update: in patients with LDL-PMF, adding ezetimibe to high-intensity statins at discharge significantly increases the likelihood of achieving the <55 mg/dL target compared to monotherapy.

A. M. Hernandez, J. M. Andreu Cayuelas, F. B. Santiago et al. · European Heart Journal · 0 citations